{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:13:55Z","timestamp":1793236435306,"version":"4.5.0"},"reference-count":53,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T00:00:00Z","timestamp":1482192000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:p>Adults with diabetes are 2\u20134 times more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in many patients with diabetes. Three independent but often interrelated variables that contribute to platelet hyperreactivity\u2014high blood glucose, oxidative stress, and elevated vascular shear forces\u2014coexist in patients with diabetes, creating a perilous concurrence of risk factors for cardiovascular events. Recent research has focused attention on the platelet-specific collagen receptor glycoprotein VI (GPVI) as a potential antithrombotic target. Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress. Importantly, drugs targeting these GPVI signaling pathways are already in existence. The potential to repurpose existing drugs is a high-gain strategy for yielding new antiplatelet agents and could have particular benefit in individuals with diabetes.<\/jats:p>","DOI":"10.2337\/db16-1098","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T20:30:24Z","timestamp":1482265824000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":26,"title":["Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling\u2014Are Useful Drugs Already Available?"],"prefix":"10.2337","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-2243","authenticated-orcid":false,"given":"Jane F.","family":"Arthur","sequence":"first","affiliation":[{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jandeleit-Dahm","sequence":"additional","affiliation":[{"name":"Baker IDI Heart and Diabetes Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,12,10]]},"reference":[{"key":"2022031303550303300_B1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.106.685628","article-title":"Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)","volume":"116","author":"Barr","year":"2007","journal-title":"Circulation"},{"key":"2022031303550303300_B2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prostaglandins.2012.01.008","article-title":"Variability in the response to antiplatelet treatment in diabetes mellitus","volume":"98","author":"Dav\u00ec","year":"2012","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2022031303550303300_B3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.thromres.2004.07.020","article-title":"Platelet physiology and thrombosis","volume":"114","author":"Andrews","year":"2004","journal-title":"Thromb Res"},{"key":"2022031303550303300_B4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/ATVBAHA.114.303413","article-title":"Current state and novel approaches of antiplatelet therapy","volume":"35","author":"Metharom","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303550303300_B5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.10.006","article-title":"Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent","volume":"29","author":"French","year":"2015","journal-title":"Blood Rev"},{"key":"2022031303550303300_B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1475-2840-8-57","article-title":"Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study","volume":"8","author":"Leung","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"2022031303550303300_B7","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"2022031303550303300_B8","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031303550303300_B9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2337\/dc09-2013","article-title":"Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent","volume":"33","author":"Gresele","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031303550303300_B10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2362.1998.00295.x","article-title":"Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects","volume":"28","author":"Ceriello","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"2022031303550303300_B11","first-page":"59","article-title":"Targeting GPVI as a novel antithrombotic strategy","volume":"5","author":"Andrews","year":"2014","journal-title":"J Blood Med"},{"key":"2022031303550303300_B12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00392-009-0109-y","article-title":"Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease","volume":"99","author":"Bigalke","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"2022031303550303300_B13","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1538-7836.2007.02590.x","article-title":"Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases","volume":"5","author":"Gardiner","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2022031303550303300_B14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/STROKEAHA.110.602532","article-title":"Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke","volume":"42","author":"Al-Tamimi","year":"2011","journal-title":"Stroke"},{"key":"2022031303550303300_B15","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.107.691279","article-title":"Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb\/IIIa blockade on infarct size, functional outcome, and intracranial bleeding","volume":"115","author":"Kleinschnitz","year":"2007","journal-title":"Circulation"},{"key":"2022031303550303300_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09537100701817224","article-title":"Platelet receptor redox regulation","volume":"19","author":"Arthur","year":"2008","journal-title":"Platelets"},{"key":"2022031303550303300_B17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1538-7836.2010.04091.x","article-title":"TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets","volume":"9","author":"Arthur","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2022031303550303300_B18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1476-5381.2012.02130.x","article-title":"The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner","volume":"168","author":"Vara","year":"2013","journal-title":"Br J Pharmacol"},{"key":"2022031303550303300_B19","doi-asserted-by":"crossref","first-page":"e000920","DOI":"10.1161\/JAHA.114.000920","article-title":"Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: lesson from chronic granulomatous disease","volume":"3","author":"Carnevale","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2022031303550303300_B20","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/db11-1243","article-title":"Platelet isoprostane overproduction in diabetic patients treated with aspirin","volume":"61","author":"Cangemi","year":"2012","journal-title":"Diabetes"},{"key":"2022031303550303300_B21"},{"key":"2022031303550303300_B22","doi-asserted-by":"crossref","first-page":"18381","DOI":"10.3390\/ijms151018381","article-title":"Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?","volume":"15","author":"Saisho","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2022031303550303300_B23","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022031303550303300_B24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0735-1097(02)02972-8","article-title":"Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus","volume":"41","author":"Gresele","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022031303550303300_B25","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1172\/JCI59291","article-title":"Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane","volume":"121","author":"Tang","year":"2011","journal-title":"J Clin Invest"},{"key":"2022031303550303300_B26","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1182\/blood-2011-06-360743","article-title":"Critical role for Syk in responses to vascular injury","volume":"118","author":"Andre","year":"2011","journal-title":"Blood"},{"key":"2022031303550303300_B27","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1182\/blood-2009-07-230268","article-title":"Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation","volume":"115","author":"Schulz","year":"2010","journal-title":"Blood"},{"key":"2022031303550303300_B28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nm.1955","article-title":"A shear gradient-dependent platelet aggregation mechanism drives thrombus formation","volume":"15","author":"Nesbitt","year":"2009","journal-title":"Nat Med"},{"key":"2022031303550303300_B29","author":"Raaz","year":"2014"},{"key":"2022031303550303300_B30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/ATVBAHA.107.140590","article-title":"The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303550303300_B31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.2007.06799.x","article-title":"Platelet glycoprotein VI-related clinical defects","volume":"139","author":"Arthur","year":"2007","journal-title":"Br J Haematol"},{"key":"2022031303550303300_B32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.yjmcc.2010.04.009","article-title":"Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin","volume":"49","author":"B\u00fcltmann","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"2022031303550303300_B33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1096\/fj.03-0464fje","article-title":"Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo","volume":"18","author":"Massberg","year":"2004","journal-title":"FASEB J"},{"key":"2022031303550303300_B34","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug Revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"2022031303550303300_B35","doi-asserted-by":"crossref","first-page":"e71193","DOI":"10.1371\/journal.pone.0071193","article-title":"The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times","volume":"8","author":"Ungerer","year":"2013","journal-title":"PLoS One"},{"key":"2022031303550303300_B36","doi-asserted-by":"crossref","first-page":"e66960","DOI":"10.1371\/journal.pone.0066960","article-title":"The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke","volume":"8","author":"Goebel","year":"2013","journal-title":"PLoS One"},{"key":"2022031303550303300_B37","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2004-06-2391","article-title":"Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice","volume":"105","author":"Gr\u00fcner","year":"2005","journal-title":"Blood"},{"key":"2022031303550303300_B38","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1182\/blood-2010-09-306142","article-title":"LXR as a novel antithrombotic target","volume":"117","author":"Spyridon","year":"2011","journal-title":"Blood"},{"key":"2022031303550303300_B39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.114.010186","article-title":"Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis","volume":"131","author":"Musumeci","year":"2015","journal-title":"Circulation"},{"key":"2022031303550303300_B40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"2022031303550303300_B41","doi-asserted-by":"crossref","first-page":"e101209","DOI":"10.1371\/journal.pone.0101209","article-title":"Discovery of novel GPVI receptor antagonists by structure-based repurposing","volume":"9","author":"Taylor","year":"2014","journal-title":"PLoS One"},{"key":"2022031303550303300_B42","doi-asserted-by":"crossref","first-page":"e0128744","DOI":"10.1371\/journal.pone.0128744","article-title":"Inhibition of glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses: the example of losartan","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"2022031303550303300_B43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1464-5491.2012.03684.x","article-title":"Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy","volume":"29","author":"Hotta","year":"2012","journal-title":"Diabet Med"},{"key":"2022031303550303300_B44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/1673-5374.177745","article-title":"Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway","volume":"11","author":"Li","year":"2016","journal-title":"Neural Regen Res"},{"key":"2022031303550303300_B45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1056-8727(02)00178-2","article-title":"Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules","volume":"16","author":"Okayama","year":"2002","journal-title":"J Diabetes Complications"},{"key":"2022031303550303300_B46","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.112.132159","article-title":"NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis","volume":"127","author":"Gray","year":"2013","journal-title":"Circulation"},{"key":"2022031303550303300_B47","article-title":"Therapeutic potential of NADPH oxidase 1\/4 inhibitors","author":"Teixeira","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2022031303550303300_B48","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/01.CIR.0000012748.58444.08","article-title":"Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase","volume":"105","author":"Guzik","year":"2002","journal-title":"Circulation"},{"key":"2022031303550303300_B49","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"2022031303550303300_B50","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/ATVBAHA.115.306883","article-title":"The novel oral Syk inhibitor, Bl1002494, protects mice from arterial trombosis and thromboinflammatory brain infarction","volume":"36","author":"van Eeuwijk","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031303550303300_B51","doi-asserted-by":"crossref","first-page":"e32894","DOI":"10.1371\/journal.pone.0032894","article-title":"Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial","volume":"7","author":"Macchia","year":"2012","journal-title":"PLoS One"},{"key":"2022031303550303300_B52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2174\/1573403X12666160504100312","article-title":"Anti-thrombotic effects of statins in acute coronary syndromes: at the intersection of thrombosis, inflammation, and platelet-leukocyte interactions","volume":"12","author":"Sexton","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"2022031303550303300_B53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbrc.2008.03.047","article-title":"Impact of cholesterol level upon APP and BACE proximity and APP cleavage","volume":"370","author":"von Arnim","year":"2008","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/66\/1\/7\/419512\/db161098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/66\/1\/7\/419512\/db161098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:31:06Z","timestamp":1667406666000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/66\/1\/7\/40155\/Platelet-Hyperreactivity-in-Diabetes-Focus-on-GPVI"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,10]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,10]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db16-1098","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,10]]}}}